Astra’s Claudin reckoning approaches
Pivotal data are due soon with the Claudin18.2-targeting ADC sonesitatug vedotin.
Pivotal Claudin18.2 candidates keep coming
New pivotal trials will soon start for LaNova’s ADC and FutureGen’s MAb.
ASCO-GI – Astellas makes a case for its Vyloy triplet
Data from the Ilustro trial support the initiation of the phase 3 Lucerna study.
ESMO 2025 preview – Astellas's third Claudin18.2 shot
Data with the T-cell engager ASP2138 look lukewarm, but could improve with combos.
Astra’s Neogene investment nosedives
NT-125 is discontinued, while two key Datroway readouts are delayed.
Sino takes out the rest of Merck’s partner
LaNova, which licensed a PD-1 x VEGF to Merck, is acquired by another Chinese player.
Elevation goes down on Claudin disaster
The honeymoon is over for Claudin18.2, as Elevation drops EO-3021.
